Skip to content

Inspection prep notes · Quality system

CAPA

Also called: corrective action, preventive action

FDA looks less at whether a CAPA procedure exists than at whether a CAPA was opened for each identified problem, carried out, and kept the problem from recurring. The findings below are quoted from Form 483s and warning letters.

What inspectors cited

1A problem was identified but no CAPA was opened

No CAPA was initiated to capture the corrective action taken and no additional corrective and/or preventive action was deemed necessary.

FDA 483 · Duke University · 2026-10-30 · View document

The audit observations were made approximately six weeks before the inspection, but no CAPAs were listed on the form, and the findings were not included in the QU’s deviation and CAPA tracking program.

FDA Warning Letter · Tentamus India Private Limited · 2026-03-10 · View document

2The same problem kept recurring and the CAPA did not prevent it

Your firm did not implement effective CAPA to reduce recurrence of severe contamination hazards including, but not limited to, operator error that had contributed significantly to recurring sterility and media-fill failures over the past five years.

FDA Warning Letter · Pharmathen International S.A. · 2026-06-16 · View document

Deviation investigations are inadequate and effective CAPAs were not implemented to prevent recurrence.

FDA 483 · Andelyn Biosciences, Inc. · 2026-10-30 · View document

3The investigation named a cause but matching actions were not implemented

Your investigation concluded that inadequacies of visual inspection were a contributing cause, but you did not implement sufficient CAPA to ensure remediation of your visual inspection program.

FDA Warning Letter · Baxter International Inc. · 2026-10-20 · View document

Your firm's Quality Unit (QU) failed to exercise adequate oversight and did not implement appropriate corrective and preventive actions in response to microbial contamination recovered within the [redacted] ISO 5 containment cell.

FDA 483 · LeeSar Inc · 2026-11-05 · View document

4CAPAs were closed without an effectiveness check

Multiple CAPAs for recurring low (b)(4) yields were closed without your required effectiveness checks.

FDA Warning Letter · Northland Nuclear Medicine, LLC · 2026-10-27

No effectiveness check was assigned within the CAPA to verify effectiveness of the corrective action and to prevent future reoccurrence of the deviation.

FDA 483 · Octapharma Dessau GmbH · 2026-10-26 · View document

5CAPAs were not started in time, or were closed past their due date

Your firm failed to assign, initiated, and implemented corrective and preventative actions (CAPAs) at an appropriate time to prevent future reoccurrence of late 15-Day Alert reports.

FDA 483 · GlaxoSmithKline Biologicals · 2026-10-30 · View document

For example, CAPA-23-004 included an extension, but the request for the extension on August 17, 2023 occurred after the initial target date of July 31, 2023, and the CAPA was closed on January 24, 2024, after the extended due date of January 5, 2024.

FDA 483 · Premier Laboratory, LLC · 2026-10-26 · View document

Questions to check against your procedures

  1. Is a CAPA opened and entered in the tracking system for each problem identified in a deviation or an audit? Are corrective actions already taken also recorded in a CAPA?
  2. When a CAPA is judged unnecessary, is the justification documented?
  3. When the same type of deviation or failure recurs, is it reviewed why the earlier CAPA did not prevent it?
  4. Is there a matching action for each root cause and contributing cause named in the investigation, and was it actually implemented?
  5. Does each CAPA have an effectiveness check assigned? Have any CAPAs been closed without one?
  6. Are CAPAs assigned and started on time? Are extensions requested before the due date passes? Have any been closed after the extended due date?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.